सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation (Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/24/000124 Dated 22-July-2025

To,

M/s Astrazeneca Pharma India Limited,
BLOCK NO 1 , 12TH FLOOR MANYATA EMBASSAY BUSINESS PARK
RACHENAHALLI OUTER RING BANGALORE (India) – 560045

Subject: Application for grant of permission to conduct Phase IV clinical trial entitled "A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease" vide Protocol No. D4800L00014 Version 1.0 dated 09 Sep 2024- regarding

Ref. No.: Your Application No. BIO/CT04/FF/2024/45717 dated 03.10.2024

Sir,

With reference to your application No.: BIO/CT04/FF/2024/45717 dated 03 OCT 2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

(I) Clinical trial sites should be geographically distributed including Government sites.
(II) CSR should be submitted to this office after completion of clinical trial.
(III) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8
(IV) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(V) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
(VI) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
(VII) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.

(VIII) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules.

(IX) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(X) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.

(XI) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.

(XII) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.

(XIII) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.

(XIV) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.

(XV) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.

(XVI) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.

(XVII) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.

(XVIII) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.01.13 11:21:26 +05'30'

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Licensing Authority

File. No. BIO/CT/24/000124

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Astrazeneca Pharma India Limited, BLOCK NO 1 , 12TH FLOOR MANYATA EMBASSAY BUSINESS PARK RACHENAHALLI OUTER RING BANGALORE (India) – 560045 to conduct Phase IV clinical trial entitled – "A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease" vide Protocol No. D4800L00014 Version 1.0 dated 09 Sep 2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 22-July-2025

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.07.22 11:59:11 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Annexure:

Details of new drug or investigational new drug:

<table>
<tr><td>Names of the new drug or investigational new drug:</td><td>Palivizumab solution for injection 100 mg/ml (r-DNA origin)</td></tr>
<tr><td>Dosage form:</td><td>50mg/0.5mL & 100 mg/mL presentations in single dose vials administered through intramuscular route</td></tr>
<tr><td>Composition:</td><td>Each vial contains:
<table>
<tr><th>Name of Ingredients</th><th>Unit Formula (50mg/vial)</th><th>Unit Formula (100mg/vial)</th></tr>
<tr><td>Palivizumab IH</td><td>50 mg</td><td>100 mg</td></tr>
<tr><td>Histidine Ph. Eur.</td><td>1.94 mg</td><td>3.9 mg</td></tr>
<tr><td>Glycine Ph. Eur</td><td>0.06 mg</td><td>3.12 mg</td></tr>
<tr><td>Water for injection Ph. Eur.</td><td>q.s.</td><td>q.s.</td></tr>
</table>
Note: Chloride, is present due to addition of HCl, Ph. Eur. for pH adjustment of formulation buffer</td></tr>
<tr><td>Indications:</td><td>Palivizumab is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:
 Infants born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
 Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia (BPD) within the last 6 months.
 Children less than 2 years of age and with haemodynamically significant congenital heart disease (CHD)</td></tr>
</table>

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1.	Christian Medical College and Hospital,Vellore, Tamil Nadu, 632004	Institutional Review Board, Christian Medical College, Torapadi Post, Bagayam, Vellore, Tamil Nadu, 632012 EC Reg. No.: ECR/326/Inst/TN/2013/RR-24	Dr Manish Kumar
2.	Surya Children's Medicare Pvt Ltd, Gate No.1, B7, Sawai Ram Singh Road, Tonk Road, Opposite SMS Hospital, C Scheme, Jaipur, Rajasthan, 302001	IEC, Maharaja Agrasen Superspecialty Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidyadhar Nagar, Jaipur – 302039 EC Reg. No.: ECR/1222/Inst/RJ/2019/RR-22	Dr Akash Sharma
3.	Yashoda Hospitals, Raj Bhavan Road, Matha Nagar, Somajiguda, Hyderabad,	Institutional Ethics Committee Yashoda Academy of Medical Educational Research, Yashoda	Dr Suresh Kumar Panuganti

	Telangana, 500082	Hospitals, Behind Hari Hara Kala Bhavan, SP Road, Secunderabad, Telangana EC Reg. No.: ECR/49/Inst/AP/2013/RR-22	
4.	Sahyadri Super Speciality Hospital, Survey No. 185A, Shastri Nagar,Near MSEB Office, Yerwada, Nagar Road, Pune, 411006, Maharashtra	Sahyadri Hospitals Private Limited Ethics Committee, 33/34B, Makarand Bhave Path, Karve Road, Pune, 411004, Maharashtra EC Reg No. ECR/493/Inst/MH/2013/RR-19	Dr Pradeep Suryawansh
5.	Manipal Hospital, No 98, Old Airport Road, Bengaluru, Karnataka, 560017	Ethics Committee Of Manipal Hospitals, No 98, Old Airport Road, Bengaluru Urban, Karnataka, 560017 EC Reg. No. ECR/34/Inst/KA/2013/RR-24	Dr N Kartik Nagesh
6.	Kolkata Medical College, 88, College street, Kolkata-700073, West Bengal	Institutional Ethics Committee, Kolkatta Medical College, 88, college street, Kolkata, 700073, West Bengal EC Reg No. ECR/287/Inst/WB/2013/RR-19	Dr Kalpana Datta